Recent Data Highlight Bavituximab's Immuno-Oncology Potential

Bavituximab and other PS-targeting antibodies have shown consistently encouraging signs of anti-tumor activity in multiple preclinical studies including models of lung, pancreatic, breast, prostate and brain cancer. Recent studies have also identified multiple immuno-stimulatory mechanisms induced by bavituximab and other PS-targeting antibodies that likely contribute to their observed anti-tumor effects.

ImVacS, the 9th Annual Immunotherapies and Vaccine Summit

• Phosphatidylserine (PS)-Targeting Antibodies Enhance Activity of Immune Checkpoint Inhibitors by Repolarizing Immunosuppressive Immune Cells Populating the Tumor Microenvironment" presentation by Jeff Hutchins. View Presentation

Cancer Research Institute Webinar

• Breakthroughs in Cancer Immunotherapy: Dr. Rolf Brekken, Reactivating Your Immune System to Fight Cancer. View webinar

2014 AACR Annual Meeting

• Antibody-mediated blockade of phosphatidylserine combined with radiation improves survival and tumor eradication in a rat model of non-small cell lung cancer. View poster
• Phosphatidylserine-targeting antibody synergizes with anti-PD-1 antibody to inhibit tumor growth in K1735 mouse melanoma model. View poster
• Targeting of Phosphatidylserine by Monoclonal Antibodies Enhances Activity of Immune Checkpoint Inhibitors in Tumors. View poster

2014 Keystone Symposium: Immune Evolution in Cancer

• Phosphatidylserine-Targeting Antibodies Induce M1 Macrophage Polarization, Promote Myeloid Derived Suppressor Cell Differentiation and Boost Tumor- Specific Immunity. View poster ,  V iew presentation slides
• Phosphatidylserine Targeting Antibodies Enhance the Activity of Immune Checkpoint Inhibitors in Tumors. View poster

2014 Keystone Symposium: HIV Pathogenesis - Virus vs. Host

• Phosphotidylserine-targeting antibody Triggers β-Chemokine Release from Monocytes by Cell-Cell Crosslinking and is a potent inhibitor of HIV-1 in vitro. View poster

2014 ITOC-1 Immunotherapy of Cancer Conference

• Bavituximab: A Novel PS-Targeting Immunotherapy for the Treatment of Cancer. View presentation slides

2013 Society for Immunotherapy of Cancer Annual Meeting

• Targeting of Phosphatidylserine by Monoclonal Antibodies Induces Innate and Specific Anti-tumor Responses.
• Phosphatidylserine-Targeting  Antibody  Induces  M1  Macrophage  Polarization,  Promotes  Myeloid  Derived   Suppressor  Cell  Differentiation,  Boosts  Tumor-­Specific  Immunity.

2013 Cambridge Healthtech Immunotherapy Congress

• Engagement of Phosphatidylserine (PS) by PS-Targeting Antibodies Blocks an Upstream Immunosuppressive Checkpoint in the Tumor Microenvironment Inducing Multiple Downstream Anti-Tumor Response Mechanisms

2013 AACR Annual Meeting

• Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice.
• Predicting Anti-tumor Responses to Phosphatidylserine Targeting Antibodies Using Tumor Imaging.
• Phosphatidylserine-Targeting ‘Betabodies’ for the Treatment of Cancer.

New York Academy of Sciences Symposium: May 1, 2012

Phosphatidylserine Asymmetry and Cell Survival: Therapeutic Applications in Cancer and Infectious Disease

On May 1, 2012, the New York Academy of Sciences (NYAS) hosted a covering the topics of the role that phosphatidylserine (PS) plays in suppressing immune response and therapeutic applications of targeting PS. Philip Thorpe, PhD, inventor or Peregrine's PS-targeting antibody technology and scientific advisor to the company, gave the final presentation, titled, Targeting Tumor Vasculature and Reactivating Tumor Immunity with Bavituximab . The entire symposium including audio replay and presentation slides are available o n the NYAS website as an e-briefing .

2012 Society for Immunotherapy of Cancer Annual Meeting

• Targeting of Phosphatidylserine by Monoclonal Antibodies Induces Innate and Specific Anti-tumor Responses.

2012 AACR Annual Meeting Clinical Poster Presentations

• A phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy naïve stage IV non-squamous non-small cell lung cancer. View poster
• A Phase I Study of Bavituximab and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. View poster
• Microparticle Generation and Activation after Treatment with Paclitaxel and Bavituximab Combination Therapy in Metastatic Breast Cancer. View poster

2012 AACR Annual Meeting Preclinical Poster Presentations

• Tumor Detection and Measurement of Responses to Chemotherapy Using Human Phosphatidylserine Targeting Antibody Fragments.
• Cure of castration-resistant prostate cancer in TRAMP mice by reactivating tumor immunity with a phosphatidylserine-targeting antibody. View poster
• Increased Fc-FcR Interaction of Human Phosphatidylserine Targeting Antibody Enhances Pro-Inflammatory and ADCC Mechanisms. View poster
• In Vivo Binding of chTNT-1/B Antibodies (Cotara) to DNA/Histone Complexes in Tumors Using Near-Infrared Optical Imaging. View poster

2012 AACR Pancreatic Cancer Conference: Progress and Challenges

• A randomized, open-label phase 2 trial of gemcitabine with or without bavituximab in patients with previously untreated stage IV pancreatic cancer.

2011 World Molecular Imaging Congress Poster Presentations

• Imaging of Human Tumor Xenografts in Mice Using Near-Infrared Fluorescent-Labeled Phosphatidylserine Targeting Antibodies

• Multimodal Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model

2011 AACR Annual Meeting Poster Presentations:

• Prostate Cancer: Targeting Phosphatidylserine to Improve Hormone Therapy of Prostate Cancer.

• Advanced Liver Cancer: Phosphatidylserine-Targeting Antibody Combined with Sorafenib has Strong Anti-Tumor Activity Against Human Hepatocellular Carcinomas in Mice.

• Mechanism of Action: Phosphatidylserine-Targeting Antibody Induces Differentiation of Myeloid-Derived Suppressor Cells into M1-Like Macrophages.

• Prostate Cancer: PS-Targeting Antibody Enhances Survival Benefit of Androgen Deprivation Therapy of Mice Bearing Syngeneic Prostate Cancer.

2010 AACR Annual Meeting Poster Presentations:

• Mechanism of Action: Phosphatidylserine on Dying Tumor Cells Suppresses Dendritic Cell Activation and Inhibits Tumor Immunity: Reversal with PS-Targeting Antibody.
• Imaging: Phosphatidylethanolamine is a marker of tumor vasculature and can be used as a target for optical imaging.

Bavituximab in Action Experiments in animals have shown that bavituximab recruits immune cells into the tumor environment.
Before Therapy	After Therapy
Key Blue: tumor cell nuclei Red: blood vessels Green: immune cells (macrophages)

Read about the growing body of published research validating bavituximab’s broad-spectrum potential...